Affordability a major issue in treating rare diseases in India: Experts

India is home to nearly 70 million rare disease patients but the country lacks significantly in terms of research treatment as well as government policies experts said here on MondayFebruary 28 is globally observed as Rare Disease Day It was set up by the European Organisation for rare diseases and was first observed in 2008Rare diseases include genetic diseases rare cancers infectious tropical diseases and degenerative diseases About 80 per cent of rare diseases are genetic in origin and hence disproportionately impact childrenAs per data that is available in India there are around 70 million rare disease patients However the number could be much higher than that and that is difficult to gauge Prof Alok Bhattacharya Professor of Biology and Head of Department at Ashoka University told IANSIt is because unfortunately neither the epidemiological studies have been done in India nor we have any idea about how many patients are there partly because there are only few centres where real diagnosis and management of these diseases happen he lamentedFurther Bhattacharya said that research on rare diseases has been very rare in IndiaBut there has been some improvement in the diagnosis of the disease due to private DNA sequencing sectors that are necessary for confirmative diagnosis of many of the diseases he notedBut there isnt much real research undergoing to understand therapy or the biology behind the rare diseases he saidIn 2017 the government came up with a National Policy for Treatment of Rare diseases It earmarked a financial allocation of Rs 100 croreIt did not talk about rare diseases per say and the allocation of Rs 100 crore for a country like this where some of the treatments can be very very expensive can treat only a few Bhattacharya saidIt was revised on the suggestions of the law courts state governments and patient advocacy groups A new policy was then formulated by January 2020 and was released by the government on March 31 2021According to Dr Anjali Taneja there have been some positive and welcoming changesYet the government could have considered more of a uniform financial allocation mechanism she saidIt is because for about 95 per cent of the rare diseases there are no therapies and treatments in India Taneja told IANSThe new policy does not mention what should be done for those 95 per cent of the rare diseases she addedTaneja recommended a relook of the policy more importantly in the implementation aspect of the policy and also the financial allocation the accessibility especially to the rare disease patients who are staying in the remote areasAccessibility and affordability is a major issue because the cost of the treatment is exorbitantly high she saidThere has been no effort by the government to address the primary issue that is from where the drugs are going to come how can we make the drugs accessible to people Bhattacharya saidRare disease patients in India are being left at the mercy of crowdfunding platforms for their treatment he lamentedBhattacharya said that in India crowdfunding will not work really wellThe amount garnered via crowdfunding will not do for even a single dayOne thing you have to realise is that a lot of these treatments are not single you have to take it for a lifetime and every dose costs lakhs of rupeesPer year costs remain very high so Rs 6000080000 will not cover for even a single dose for two weeksTo top it there are hundreds of diseases for which there is absolutely no treatmentWhat do you tell those patients Is it bad luck that they have that disease for which there is no treatment So I think in those terms the rare disease policy does not really answer any questions or any issues related to rare disease patients he saidPeople living with rare diseases see no hope today Hope can only come if the government can spend a few hundred crores on developing platforms like gene therapy gene editing platforms Bhattacharya addedThe best treatment for rare diseases would be to come up with a vaccine just like India did for Covid It is the only way we can make treatment cheaper and accessible to everyoneThis story has been sourced from a third party syndicated feed agencies Midday accepts no responsibility or liability for its dependability trustworthiness reliability and data of the text Midday managementmiddaycom reserves the sole right to alter delete or remove without notice the content in its absolute discretion for any reason whatsoever